REMARKS

This amendment is filed in response to the Official Action mailed March 28, 2007 for the above-referenced application, and is believed to place this application in form for allowance.

Claim 1 has been canceled without prejudice, thus rendering the rejection for lack of written description moot.

Independent claim 14 has been amended to specify that the oligonucleotide is one targeted to clusterin. This amendment is supported throughout the application, but in particular at Page 2, lines 16-17.

Claim 14 ise rejected as anticipated by WO 99/51259 of Krieg et al. This reference relates to non-sequence specific nucleotide therapeutics for diseases including melanoma. Claims 2, 11 and 14 are rejected as anticipated by newly cited Saijo et al. Claims 1-5, 11 and 14 are also rejected as obvious over the combination of Saijo et al. and Bennett. Saijo et al discloses p120 targeted RNAi in the treatment of melanoma.

The Examiner argues that since melanoma cells are being reduced, so is clusterin, and thus she argues that the processes done in the references meet the limitations of the claims. The Examiner also states that "the instant claims do not recite that the agent or nucleotide needs to have any specific relationship with clusterin." Without agreeing that the scope of the claims chosen by the Examiner is reasonable, Applicants have amended claim 14 to state that the oligonucleotide is targeted to clusterin. None of the references cited by the Examiner has anything to do with clusterin, and therefore Applicants believe that this rejection overcomes the rejections.

For this reason, this application is now believed to be in form for allowance, and such action is respectfully urged.

Respectfully submitted,



Marina T. Larson Ph.D.
PTO Reg. No. 32,038
Attorney for Applicant
(970) 262-1800